<SEC-DOCUMENT>0001213900-21-066382.txt : 20211220
<SEC-HEADER>0001213900-21-066382.hdr.sgml : 20211220
<ACCEPTANCE-DATETIME>20211220164522
ACCESSION NUMBER:		0001213900-21-066382
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20211220
FILED AS OF DATE:		20211220
DATE AS OF CHANGE:		20211220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		211505788

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea152703-6k_scisparcltd.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of December 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20 Raul Wallenberg Street, Tower A,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Tel Aviv 6971916 Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp; Form 40-F
&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">On December 20,
2021, SciSparc Ltd. (the &ldquo;Company&rdquo; or &ldquo;SciSparc&rdquo;) issued a press release titled &ldquo;SciSparc Announces Approval
of Uplisting to The Nasdaq Capital Market.&rdquo; A copy of this press release is furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Report on Form 6-K is
incorporated by reference into the registration statements on Form F-3 (File No.&nbsp;<U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018007936/ff32018_therapixbio.htm">333-225745</A></U>&nbsp;and File No.&nbsp;<U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390019016523/ff32019_therapixbio.htm">333-233417</A></U>)
and on Form S-8 (File No.&nbsp;<U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A></U>) of the Company, filed with the Securities and Exchange Commission, to be a part thereof
from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="ea152703ex99-1_scisparcltd.htm">Press release titled: &ldquo;SciSparc Announces Approval of Uplisting to The Nasdaq Capital Market.&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B><U>SciSparc Ltd.</U></B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Date: December 20, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; vertical-align: top"><FONT STYLE="font-size: 10pt">/s/ Oz Adler</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 31%"><FONT STYLE="font-size: 10pt">&nbsp;Oz Adler</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea152703ex99-1_scisparcltd.htm
<DESCRIPTION>PRESS RELEASE TITLED: "SCISPARC ANNOUNCES APPROVAL OF UPLISTING TO THE NASDAQ CAPITAL MARKET."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SciSparc Announces Approval of Uplisting to The Nasdaq Capital Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TEL AVIV, Israel, Dec. 20, 2021 /PRNewswire/ -- SciSparc
Ltd. (OTCQB: SPRCF) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of
the central nervous system (the &ldquo;Company&rdquo; or &ldquo;SciSparc&rdquo;), today announced that its ordinary shares have been approved
for listing on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;SPRC&rdquo;. Trading of the Company&rsquo;s ordinary
shares on Nasdaq is expected to begin on December 22, 2021. The Company&rsquo;s shares will continue to trade on the OTCQB under the symbol
&ldquo;SPRCF&rdquo; until trading on Nasdaq commences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Uplisting our shares to Nasdaq is a great way
to end the year!&rdquo; said Amitai Weiss, Chief Executive Officer of SciSparc. &ldquo;We have been working diligently toward this milestone
since announcing our rebranding earlier this year. It reflects the improvements we have made to the fundamental value of the Company,
including a growing patent portfolio, advancements in our clinical studies and notable additions to our leadership team.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Trading on Nasdaq should increase our visibility
in the market, as well as provide broader access to individual and institutional investors going forward. I am confident that all of these
developments will enhance our ability to develop the therapeutics that will improve the lives of those suffering from central nervous
system disorders,&rdquo; concluded Mr. Weiss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>About SciSparc (OTCQB:SPRCF):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies
and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs
based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome, for the treatment of obstructive
sleep apnea and Alzheimer&rsquo;s disease and Agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum
disorder and epilepsy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Forward-Looking Statements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements
within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995 and other U.S. federal
securities laws. For example, SciSparc is using forward-looking statements when it discusses the expected medical benefits of its therapeutics
and drug candidates, the expected benefits of becoming a company listed on Nasdaq and the anticipated first date of trading of the Company&rsquo;s
ordinary shares on Nasdaq. Because such statements deal with future events and are based on SciSparc&rsquo;s current expectations, they are
subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release
are subject to other risks and uncertainties, including those discussed under the heading &ldquo;Risk Factors&rdquo; in SciSparc&rsquo;s Annual
Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the&nbsp;&ldquo;SEC&rdquo;) on March 30, 2021, and in subsequent
filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">IR@scisparc.com<BR>
Tel: +972-3-6167055</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Logo -&nbsp;https://mma.prnewswire.com/media/1434686/SciSparc_Ltd_Logo.jpg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &0 9 # 2(  A$! Q$!_\0
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MX1C_ '\>GZ5Z56=HNB:=X>TN'3M+M4MK6(?*B#J>Y)[GWK1H **** "BBB@
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MBHBC"JHP /2I* ,'4_!GAW6M6CU34](M[N\C01I),N[ !R..G>MT# P*6B@
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M-3G$<48^5<_-(W95'<FOGKP3/\4->T R^&?$JSQ0-Y<EM-.IDB]/OCH>W/\
M*M>W^#'C;Q7J:77C/7=L:GD>;YTF/11]U: *'P?T^]\9?%.]\7749$%O)).[
M=O-?(51] 3^5?2U9'AWP[IGA?1X=+TJW$-M$,^K.W=F/<GUK7H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>$H/!7AN'1X+J>Z",7:24]6/7:/X1[4 =)1110 4444 %%%% !1110 4444
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MM+==J)G/?/)]>:T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK*A52@/W5^OYGZ5Z]IFG6VDZ7:Z=:)LMK:)8HU] !B@"Y1110 4444 %%%%
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MVP_]GK'_ &D/^1QTK_KP_P#9VK8_9HZ>(O\ MA_[/0![_1110 4444 %%%%
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M,UU-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ,!/1OP_*@#MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;D3#74PMXC_LH,G]6_2@#W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HKB?B)\1-.\!Z27D*SZG,#]FM<\M_M-Z**X;X*WGC?7M8U'7M
M3O';1KHDLLPR)).WE#^$#IZ?C0![?1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>=?$GXJ:=X'M&M+<I=ZU(O[NW!XB
MST9_3Z=37HM>63_!'1+SQ_<>(+N:2:RE;SC8MD@RGKEO[OM_2@#SCP)\.]8^
M)>M-XI\5RS'3I'WY?A[G_97^ZG^17TG:6D%C:16MK"D,$*A(XT&%4#H *?%'
M'#$D42*B(-JJHP%'I4E !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !15'4]6T_1;)[S4[V&TMTZR2N%%>)^,?V@06:P\'VK2RL=HO
M9D[_ .PG?\?RH ]U\^(3B#S$\XJ6$>[YB,]<>E2UX#\-/ GCB\\66_C+7M0G
MM&')6X^::X4]5*_PK]?3I7OU !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%07-W;6<?F75Q% @_BE<*/UKDM6^*_@G1@PGUZWFD7_ )9V
MV9C_ ..Y% ':45X7K7[2&GQ;DT319[@]!)=.(U_[Y&3_ "KV?2=0CU;2++48
M?]7<PI,OMN&: +M5KZ.YDT^X2SE6*Y:-A%(RY"OC@D?6K-% 'S-:?"WX@^/M
M4:[\4WLMK"KE3)=-EL \^7&.@_*O9?!_PP\->#%62SM!<7P'-Y<_,_\ P'LO
MX5VE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(1N!'K
M2T4 ?.,OP#\5ZMJ5Q+J&MVR0&5BADDDF?;GCC'I[UTNE?LY:#;E6U35;V\;N
ML0$2_P!3^M>TT4 <IHOPW\(:!M:QT*T\U>DLR^:_YMFNI50J@*  .@%.HH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
